New COVID variant JN.1 symptoms, latest studies on Paxlovid rebound and Hydroxychloroquine

Release Date:

AMA Annual Meeting 2024: Advocacy progress on Medicare payment reform, prior authorization and more

AMA Senior Vice President of Advocacy, Todd Askew, provides an update at the AMA Annual Meeting on the advocacy efforts of the AMA so far this year on the top priorities for physicians. American Medical Association CXO Todd Unger hosts.

🩺 The AMA is your powerful ally in patient care. Join now: https://ama-assn.co/JoinRenew

🤝 Learn more about grant funding through AMA Scope of Practice Partnership: https://ama-assn.co/SOPP

📨 Stay up to date on all the latest advocacy news by subscribing to AMA Advocacy Update: https://ama-assn.co/Advocacy_newsletter

💪 See how the AMA fights for physicians: https://ama-assn.co/FightingForDocs

New COVID variant JN.1 symptoms, latest studies on Paxlovid rebound and Hydroxychloroquine

Title
New COVID variant JN.1 symptoms, latest studies on Paxlovid rebound and Hydroxychloroquine
Copyright
Release Date

flashback